Patrick J. Cimino, Sonali Arora, Tobias Bonifert, Norman Boiani, Tatsuya Ozawa, Barbara Oldrini, Frank Szulzewsky, Eric C. Holland, Hamid Bolouri, Massimo Squatrito, Siobhan S. Pattwell, Colin Correnti, Patrick J. Paddison, Pia Hoellerbauer, Benjamin G. Hoffstrom, John R. Silber, United States Department of Health & Human Services National Institutes of Health (NIH) - USA, American Cancer Society, French National Research Agency (ANR), Alzheimer's Disease Research Center, United States of Department of Health & Human Services, and French Development Agency
Independent scientific achievements have led to the discovery of aberrant splicing patterns in oncogenesis, while more recent advances have uncovered novel gene fusions involving neurotrophic tyrosine receptor kinases (NTRKs) in gliomas. The exploration of NTRK splice variants in normal and neoplastic brain provides an intersection of these two rapidly evolving fields. Tropomyosin receptor kinase B (TrkB), encoded NTRK2, is known for critical roles in neuronal survival, differentiation, molecular properties associated with memory, and exhibits intricate splicing patterns and post-translational modifications. Here, we show a role for a truncated NTRK2 splice variant, TrkB.T1, in human glioma. TrkB.T1 enhances PDGF-driven gliomas in vivo, augments PDGF-induced Akt and STAT3 signaling in vitro, while next generation sequencing broadly implicates TrkB.T1 in the PI3K signaling cascades in a ligand-independent fashion. These TrkB.T1 findings highlight the importance of expanding upon whole gene and gene fusion analyses to include splice variants in basic and translational neuro-oncology research., Tropomyosin receptor kinase B (TrkB), encoded by the neurotrophic tyrosine receptor kinase 2 (NTRK2) gene, exhibits intricate splicing patterns and post-translational modifications. Here, the authors perform whole gene and transcript-level analyses and report the TrkB.T1 splice variant enhances PDGF-driven gliomas in vivo and augments PI3K signaling cascades in vitro.